Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Multiple Myeloma Stage I Clinical Trial

Official title:
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Status Terminated

Clinical Trial Summary

Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma. It is the aim of this study to investigate whether zoledronic acid has an influence on the progression of multiple myeloma.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00171925
Study type	Interventional
Source	Novartis
Contact
Status	Terminated
Phase	Phase 3
Start date	August 2000
Completion date	November 2008

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03792620` - Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	Phase 3
	Active, not recruiting	`NCT03428373` - Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma	Phase 2/Phase 3